Form 4: Phibro CEO Sells Shares Under 10b5-1 Plan

Phibro Animal Health Corp's President and CEO, Jack Bendheim, along with BFI Co., LLC, reported sales of Class A Common Stock totaling 7,040 shares under a pre-arranged 10b5-1 trading plan.

Summary

• Jack Bendheim, President and CEO of Phibro Animal Health Corp, and BFI Co., LLC, reported transactions involving Phibro Class A Common Stock.
• On November 4, 2025, 25,000 shares of Class B Common Stock were converted into Class A Common Stock.
• Between November 4 and November 5, 2025, a total of 7,040 Class A Common Stock shares were sold by BFI Co., LLC.
• These sales were executed under a Rule 10b5-1 trading plan established on May 30, 2025.
• The sales occurred at weighted average prices ranging from $40.9805 to $43.6205 per share.
• Following these transactions, BFI Co., LLC indirectly holds 62,400 Class A Common Stock and 20,061,034 Class B Common Stock.
• Jack Bendheim directly holds 16,840 Class A Common Stock.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While insider selling can sometimes be viewed negatively, the fact that these sales were conducted under a pre-arranged 10b5-1 plan mitigates immediate concerns. It represents a planned divestment rather than a reaction to adverse company news.

Positives

• The transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned divestment strategy rather than a reaction to immediate negative news.

Negatives

• Significant insider selling by the President and CEO, even if pre-planned, can sometimes be perceived negatively by the market.
• The sales occurred at varying prices, with some transactions at lower prices ($40.9805) compared to others ($43.6205).

Risks

• Potential for negative market perception due to insider selling, which could put downward pressure on the stock price.
• The disclosure notes that Jack Bendheim disclaims beneficial ownership of the securities held by BFI Co., LLC except to the extent of his pecuniary interest, which could imply complex ownership structures.

Future Outlook

NA

Management Comments

• Jack Bendheim, a reporting person, director and officer of Phibro Animal Health Corporation (the 'Issuer'), exercises voting and dispositive power over BFI and may be deemed to have shared voting and investment power over the securities held by BFI.
• Mr. Bendheim disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing reports routine insider transactions and does not provide information directly related to broader industry trends or competitive landscape.

Related Party Transactions

• The transactions involve Jack Bendheim, President and CEO, and BFI Co., LLC, over which Mr. Bendheim exercises voting and dispositive power. This constitutes a related party transaction in the context of insider reporting.

Stakeholder Impact

• Shareholders: May perceive insider selling as a negative signal, potentially leading to short-term price volatility, though the 10b5-1 plan mitigates this.
• Management/Employees: No direct impact indicated, as this is a personal trading plan for the CEO.

Key Dates

Recommendation

The insider sales by CEO Jack Bendheim and BFI Co., LLC were executed under a pre-arranged Rule 10b5-1 trading plan. This indicates a systematic, pre-planned divestment strategy rather than a reaction to new, material non-public information. While insider selling can sometimes be a bearish signal, the context of a 10b5-1 plan suggests these are routine liquidity or diversification events. Without additional company-specific news or broader market context, these transactions alone do not warrant a change from a 'hold' position. Investors should monitor future company performance and broader market conditions.

Keywords

Phibro Animal Health, PAHC, Insider Trading, Form 4, Jack Bendheim, Stock Sale, 10b5-1 Plan, CEO Stock Sale, Beneficial Ownership